Occuity, a UK MedTech company at the forefront of the burgeoning field of Oculomics, is proud to announce two major milestones in its technological and intellectual property development.
Occuity files a patent as part of its Innovate UK-supported SD1 project to develop a non-invasive screening tool for diabetes.
A further patent has been granted which covers the company’s novel high-speed, long-range scanning technology.
Occuity has successfully filed a new patent application and has also had a key patent granted, strengthening its position in the market, and underscoring its commitment to revolutionising disease screening and monitoring by using the eye as a window on the health of the body. The company also report 4 patents now moving from their initial UK filing to national filings abroad. Two are being filed in the EU and US and two in the EU, US, China, and India.
Recent Patent Application Filed
Occuity's latest patent application has been filed as part of its Innovate UK-supported SD1 project. In this project, Occuity is developing a non-invasive screening tool for diabetes, a problem that is predicted to affect 1.3 billion people by 2050. This new patent is a testament to Occuity's innovative approach to healthcare, as it protects the proprietary technology used in the prototype SD1 diabetes screening device. This technology builds on the company’s existing PM1 and AX1 optical platforms and is a critical enabler in the development of compact, handheld devices that will be both accessible and cost-effective.
Dr. Robin Taylor, CTO and Co-founder of Occuity expressed his enthusiasm saying, "Screening for chronic diseases is something that I and the Occuity team are deeply passionate about; we hope to fundamentally change the approach to healthcare with a move toward preventative medicine.
This patent application is a huge step toward our long-term goal of achieving an easy-to-develop, cost-effective, screening tool for chronic diseases such as Diabetes and Alzheimer’s Disease.”
Key Patent Granted
The patent application follows hot on the heels of another significant development for the company, the recent patent approval covering a novel high-speed scanning approach used across the company’s entire product portfolio. This patent encompasses a unique electro-mechanical design that allows precise linear scanning over a long range at over 200 scans per second.
Dr. Taylor, who was the lead engineer on the invention, remarked, "The granting of this patent is crucial in protecting a key enabling technology that is fundamental to achieving our mission of assessing someone’s health by simply performing a quick scan of their eye.
Commenting on the broader implications of these patents, Occuity CEO and Co-founder, Dr. Dan Daly, added, "The patent grant and this new patent application not only secures our unique technology but also enhances our position as a leader in the growing field of Oculomics. They are vital components in our mission to use the eye as a window into the overall health of the body. It's a testament to our potential in the field of optical scanning and eye health and advances our mission to transform disease detection, diagnosis, and management through non-invasive techniques."
